Lundbeck and Otsuka`s Rxulti® (brexpiprazole) receives positive opinion in EU from CHMP for the treatment of schizophrenia in adults
(WorldNews Denmark)

Press release Valby, 1 June 2018 A final decision from the European Commission is expected within 67 days. H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion on Rxulti®(brexpiprazole) for the treatment of schizophrenia in adults.1 A final decision from the European Commission is expected within 67 days. Brexpiprazole is a once-daily second generation (atypical) oral antipsychotic; it provides a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A...